Cognition Therapeutics, Inc. Earnings Per Share (Diluted)
Cognition Therapeutics, Inc. (CGTX) reported Earnings Per Share (Diluted) of -$0.04 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-07
- Cognition Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.04.
- Cognition Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.05.
- Cognition Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.04.
- Cognition Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.06.
- Cognition Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was -$0.32.
- Cognition Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$0.86.
- Cognition Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$0.86.
- Cognition Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$0.91.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.04 10-Q · filed 2026-08-07 | -$0.09 10-Q · filed 2026-08-07 | -$0.13 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-07 |
| 2026-03-31 | -$0.05 10-Q · filed 2026-05-08 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-07 |
| 2025-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.32 10-K · filed 2026-03-26 |
| 2025-09-30 | -$0.06 10-Q · filed 2025-11-06 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.30 10-Q · filed 2025-11-06 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-08-07 |
| 2025-06-30 | -$0.11 10-Q · filed 2026-08-07 | -$0.24 10-Q · filed 2026-08-07 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-08-07 |
| 2025-03-31 | -$0.14 10-Q · filed 2026-05-08 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-08-07 |
| 2024-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-03-26 | -$0.86 10-K · filed 2026-03-26 |
| 2024-09-30 | -$0.25 10-Q · filed 2025-11-06 | -$0.42 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.69 10-Q · filed 2025-11-06 | -$0.94 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.18 10-Q · filed 2025-08-07 | -$0.44 10-Q · filed 2025-08-07 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.92 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | -$0.27 10-Q · filed 2025-05-07 | -$0.53 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.76 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.92 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2023-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.49 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.65 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$0.86 10-K · filed 2025-03-20 |
| 2023-09-30 | -$0.22 10-Q · filed 2024-11-13 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.59 10-Q · filed 2024-11-13 | -$0.79 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.16 10-Q · filed 2024-08-08 | -$0.37 10-Q · filed 2024-08-08 | -$0.57 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.84 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-03-31 | -$0.21 10-Q · filed 2024-05-07 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.69 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$0.94 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2022-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$0.48 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$0.73 derived: net income ÷ weighted average shares · filed 2024-03-26 | -$0.91 10-K · filed 2024-03-26 |
| 2022-09-30 | -$0.29 10-Q · filed 2023-11-02 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$0.71 10-Q · filed 2023-11-02 | -$1.08 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2022-06-30 | -$0.25 10-Q · filed 2023-08-08 | -$0.43 10-Q · filed 2023-08-08 | -$0.79 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.24 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2022-03-31 | -$0.17 10-Q · filed 2023-05-04 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.02 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.48 derived: net income ÷ weighted average shares · filed 2023-11-02 |
| 2021-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$1.07 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$1.77 derived: net income ÷ weighted average shares · filed 2023-03-23 | -$3.13 10-K · filed 2023-03-23 |
| 2021-09-30 | -$8.12 10-Q · filed 2022-11-14 | -$7.63 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$14.87 10-Q · filed 2022-11-14 | -$10.90 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$4.77 10-Q · filed 2022-08-09 | -$6.53 10-Q · filed 2022-08-09 | -$5.60 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$8.88 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-03-31 | -$1.64 10-Q · filed 2022-05-11 | -$3.03 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$6.34 derived: net income ÷ weighted average shares · filed 2022-11-14 | |
| 2020-12-31 | -$3.48 derived: net income ÷ weighted average shares · filed 2022-03-30 | -$6.81 derived: net income ÷ weighted average shares · filed 2022-03-30 | -$23.76 10-K · filed 2022-03-30 | |
| 2020-09-30 | -$5.31 10-Q · filed 2021-11-17 | -$18.34 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |